Can-Fite BioPharma Announces the Initiation of Patient Enrolment for the Phase 2/3 Psoriasis Study with its Lead Drug CF101
8/1/2011 10:51:16 AM
PETAH-TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange announced today that it has commenced patient enrolment in a phase 2/3 clinical trial of CF101 for the treatment of Psoriasis. This clinical trial will be conducted in 17 medical centers in the United States, Europe and Israel under an open IND.
comments powered by